bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 11 citations · 12 references
PharmacyInfectious DiseasesPharmacotherapyDrug DiscoveryMolecular VirologyVirologyAntiretroviral TherapyAntiviral AgentsAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyViral InfectionsAntiviral TherapeuticsDrug Candidate OptimizationProtease InhibitorsSars-cov-2 Antiviral TherapySars-cov-2 InfectionViral Protease FunctionViral Protease InhibitionViral Proteases
ABSTRACT COVID-19 has caused over 900,000 deaths worldwide as of September 2020, and effective medicines are urgently needed. Lopinavir was identified as an inhibitor of the HIV protease, and a lopinavir-ritonavir combination therapy was reported to be beneficial for the treatment of SARS and MERS. However, recent clinical tests could not prove that lopinavir-ritonavir therapy was an effective treatment for COVID-19. In this report, we examined the effect of lopinavir and ritonavir to the activity of the purified main protease (Mpro) protein of SARS- CoV-2, the causative virus of COVID-19. Unexpectedly, lopinavir and ritonavir did not inhibit Mpro activity. These results will aid the drug candidate selection for ongoing and future COVID-19 clinical trials.
12
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Bin Cao, Yeming Wang, Danning Wen et al. · New England Journal of Medicine · 2020 · 5.5K citations · Full text
Inhibition of SARS-CoV 3CL protease by flavonoids
Seri Jo, Suwon Kim, Dong Hae Shin et al. · Journal of Enzyme Inhibition and Medicinal Chemistry · 2019 · 710 citations · Full text